News 
Coin Information 
About us 
Customer Service 
Genmab ($GMAB) used two of oncology’s biggest scientific stages—ASCO 2026 and the EHA 2026 Congress—to map out an aggressive expansion plan for its cancer portfolio, highlighting new data around its bispecific antibody epcoritamab and early progress in solid tumors and AI-driven R&D. The updates underscore the company’s push to broaden epcoritamab’s reach across multiple blood cancers while diversifying beyond its traditional hematology stronghold.
Across presentations released around the conferences, Genmab placed particular emphasis on epcoritamab’s potential in older and harder-to-treat patient populations. In newly diagnosed diffuse large B-cell lymphoma (DLBCL), the company said epcoritamab as a monotherapy and as part of epcoritamab-based combinations delivered high response rates in elderly patients—an important segment where clinicians often face a tradeoff between efficacy and tolerability due to limited ability to withstand intensive regimens.
Momentum was also highlighted in follicular lymphoma (FL), where Genmab presented subgroup findings from EPCORE FL-1. The company said the regimen pairing epcoritamab with rituximab and lenalidomide—often referred to as the R2 backbone—generated consistent efficacy and safety signals across patient subsets. In additional phase 3 pivotal data, Genmab reported that EPKINLY (epcoritamab-bysp) combined with R2 provided clinical benefit in relapsed or refractory FL, reinforcing the company’s view that epcoritamab can compete not only as a single agent but as a scalable partner in combination strategies.
Genmab also disclosed topline results from the phase 3 EPCORE DLBCL-1 trial in relapsed or refractory DLBCL, positioning epcoritamab as a potential option for later-line treatment. However, the company did not provide detailed numerical outcomes or comparative breakdowns in the update, meaning investors and clinicians will likely wait for full conference presentations and peer-reviewed publication to assess the magnitude of benefit, safety profile, and how the data stack up against existing standards of care.
Beyond lymphoma, Genmab presented early clinical results targeting Richter transformation (RT), a high-risk condition in which chronic lymphocytic leukemia (CLL) progresses into a more aggressive lymphoma. In findings from the phase 1b/2 EPCORE CLL-1 study, the company said epcoritamab showed promise both as a standalone therapy and in combinations. Given the historically poor outcomes in RT and limited effective options, any credible signal of activity tends to draw heightened attention, though early-stage data typically require cautious interpretation.
In solid tumors, Genmab reported safety and tolerability data for the combination of rinatabart sesutecan (Rina-S) and bevacizumab in patients with advanced ovarian cancer. While the readout was framed as an early evaluation focused more on safety than efficacy, the program signals Genmab’s intent to broaden its oncology footprint beyond hematologic malignancies—a strategic move that could expand its addressable market but also introduces development risk typical of solid-tumor pipelines.
The company paired its clinical updates with operational changes aimed at increasing R&D throughput. Genmab said it is updating portfolio prioritization to improve capital and resource allocation, and announced a collaboration with Anthropic to integrate ‘agentic AI’ into research and development. The goal, Genmab indicated, is to accelerate target discovery, streamline clinical trial design, and speed up data interpretation—an approach increasingly pursued across big pharma and biotech as datasets grow and development timelines remain a competitive differentiator.
On the corporate front, Genmab also said it has completed a public tender offer for common shares of Merus N.V. and entered a subsequent offering period. The move points to a parallel strategy of expanding through asset and platform access, not just internal pipeline development, as competition intensifies in bispecific antibodies and next-generation oncology modalities.
Overall, Genmab’s ASCO and EHA disclosures painted a multi-track growth narrative: scaling epcoritamab across lymphomas and other hematologic settings, opening a beachhead in ovarian cancer, and modernizing its development engine with AI while reshaping its asset base. Market focus is now likely to shift toward the full datasets—particularly in phase 3 programs—regulatory discussions, and the pace at which Genmab can convert clinical signals into durable commercial expansion.
🔎 Market Interpretation
- Conference-driven re-rating catalyst: Genmab used ASCO 2026 and EHA 2026 to position epcoritamab as a platform-like asset across multiple B-cell malignancies; near-term market attention will likely center on the completeness and quality of forthcoming phase 3 readouts (especially EPCORE DLBCL-1) and how they compare to existing standards.
- Confidence signal, but data opacity remains: The company disclosed topline phase 3 outcomes in relapsed/refractory DLBCL without detailed numbers, which can limit immediate investor conviction until full efficacy, safety, and subgroup breakdowns are released in presentations/publications.
- Combination scalability narrative: Emphasis on epcoritamab working not only as monotherapy but also as a backbone partner (e.g., with R2) supports a broader commercial positioning in FL and potentially other settings, depending on tolerability and sequencing vs. competitors.
- Expansion beyond hematology increases upside and risk: The ovarian cancer program (Rina-S + bevacizumab) is currently framed as safety/tolerability-focused, indicating early innings—potentially expanding TAM, but with typical solid-tumor attrition risk.
- Operational leverage through AI: The Anthropic “agentic AI” collaboration is framed as an R&D speed/throughput play (target discovery, trial design, interpretation). Markets may view this as execution-enhancing, but benefits are often hard to quantify near-term.
- Parallel inorganic strategy: The Merus tender offer suggests Genmab is also pursuing external platform/asset access, a strategic hedge in a crowded bispecific landscape and a potential pipeline acceleration lever.
💡 Strategic Points
- Prioritize elderly and hard-to-treat segments: Highlighted data in newly diagnosed DLBCL among elderly patients targets a clinically important population where tolerability constraints can differentiate therapies and support adoption.
- Strengthen follicular lymphoma positioning with R2: Subgroup consistency from EPCORE FL-1 and pivotal phase 3 benefit with EPKINLY + R2 supports a strategy of embedding epcoritamab into established regimens rather than relying solely on single-agent use.
- De-risk Richter transformation with early signals: EPCORE CLL-1 activity in RT (monotherapy and combinations) addresses a high-unmet-need niche; next milestones are signal durability, safety management, and expansion cohorts.
- Clarify EPCORE DLBCL-1 value proposition: Key forthcoming diligence points include response depth/duration, CRS/ICANS management, discontinuation rates, and performance vs. CAR-T, ADCs, and other bispecifics in later-line DLBCL.
- Solid-tumor beachhead strategy: Rina-S + bevacizumab readout suggests an initial “permission to proceed” step; strategic inflection will be whether efficacy emerges without prohibitive toxicity in advanced ovarian cancer.
- Portfolio reprioritization as capital discipline: Updating portfolio prioritization indicates a focus on resource allocation to the most value-accretive programs—often a positive if it shortens timelines or reduces spend on low-probability assets.
- Watch for regulatory and sequencing pathways: Commercial expansion depends on how epcoritamab is placed in treatment lines (frontline vs. relapsed/refractory), combination label breadth, and real-world feasibility for older patients.
📘 Glossary
- ASCO: American Society of Clinical Oncology annual meeting, a major venue for oncology clinical data releases.
- EHA: European Hematology Association Congress, a leading conference for blood cancer and hematology updates.
- Bispecific antibody: An antibody engineered to bind two different targets (often bringing immune cells to cancer cells).
- Epcoritamab (EPKINLY): Genmab/partnered bispecific antibody therapy highlighted across lymphoma and CLL/RT studies.
- DLBCL: Diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma.
- FL: Follicular lymphoma, typically an indolent (slower-growing) non-Hodgkin lymphoma.
- R2 regimen: Rituximab + lenalidomide backbone used in certain lymphoma treatments.
- Relapsed/Refractory (R/R): Disease that has returned after treatment (relapsed) or did not respond (refractory).
- Phase 1b/2, Phase 3: Clinical trial stages; early studies assess safety and initial activity, while phase 3 tests efficacy vs. standard approaches for potential approval.
- Richter transformation (RT): Progression of CLL into an aggressive lymphoma; associated with poor prognosis.
- CLL: Chronic lymphocytic leukemia, a blood cancer of lymphocytes.
- Bevacizumab: An anti-VEGF antibody often used to inhibit tumor blood vessel growth in several cancers.
- Safety/tolerability readout: Early evaluation focused on adverse events and how well a therapy can be administered, not necessarily powered for efficacy conclusions.
- Agentic AI: AI systems designed to autonomously plan and execute multi-step tasks (e.g., literature synthesis, hypothesis generation, trial design support) under human oversight.
- Tender offer: A public proposal to purchase shares from shareholders, often used in acquisitions or strategic stake-building.
Comment 0